ANI Pharmaceuticals (ANIP) said Thursday it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.

The FDA granted the drug a competitive generic therapy designation, providing ANI with 180 days of market exclusivity, the company said.

Motegrity, or prucalopride, is intended to treat a type of constipation called chronic idiopathic constipation.

Shares of ANI gained more than 1% in recent premarket activity Thursday.

Price: 56.10, Change: +0.82, Percent Change: +1.48